The ASCT2 inhibitor benzylserine can significantly reduce glutamine transport in tumor cells, inhibit the mTOR signaling pathway, and reduce the expression of cell cycle regulators, thus inhibiting cell cycle progression [142]. Here, MTOR is linked to neoplasm.